Lineage Cell Therapeutics, Inc.
Tel Aviv Stock ExchangeTotal Valuation
Lineage Cell Therapeutics, Inc. carries a market capitalization of 1.02B, placing it among publicly traded companies globally. Its enterprise value stands at 35.80B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.02B |
| Enterprise Value | 35.80B |
Share Statistics
Lineage Cell Therapeutics, Inc. currently has 249.30M shares outstanding.
| Shares Outstanding | 249.30M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 2,426.00, and the price-to-book ratio stands at 619.82.
| PE Ratio | N/A |
| PS Ratio | 2,426.00 |
| PB Ratio | 619.82 |
| P/TBV Ratio | 3,473.21 |
| P/FCF Ratio | -1,695.64 |
| P/OCF Ratio | -1,621.54 |
Enterprise Valuation
| EV / Sales | 2,422.47 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Lineage Cell Therapeutics, Inc. maintains a current ratio of 6.89, meaning it holds 6.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.89 |
| Quick Ratio | 6.65 |
| Debt / Equity | 4.54 |
| Debt / EBITDA | -0.11 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -92.02 |
| Return on Assets (ROA) | -58.03 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Lineage Cell Therapeutics, Inc.'s stock has gained approximately 23.8254% over the past 52 weeks. The 50-day moving average sits at 260.10, while the 200-day moving average is 69.08.
| Beta (5Y) | N/A |
| 52-Week Price Change | 23.8254% |
| 50-Day Moving Average | 260.10 |
| 200-Day Moving Average | 69.08 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Lineage Cell Therapeutics, Inc. generated 14.78M in revenue and converted that into -64.21M in net income, yielding earnings per share of -0.27. EBITDA reached -22.14M, while operating income came in at -22.87M.
| Revenue | 14.78M |
| Gross Profit | 14.67M |
| Operating Income | -22.87M |
| Pretax Income | -69.29M |
| Net Income | -64.21M |
| EBITDA | -22.14M |
| EBIT | -22.87M |
| Earnings Per Share (EPS) | -0.27 |
Balance Sheet
Lineage Cell Therapeutics, Inc. holds 53.38M in cash and equivalents against 2.39M in total debt, resulting in a net debt position of -35.94M. Total book value stands at 57.85M, with working capital of 48.02M providing operational flexibility.
| Cash & Cash Equivalents | 53.38M |
| Total Debt | 2.39M |
| Net Debt | -35.94M |
| Equity (Book Value) | 57.85M |
| Book Value Per Share | 0.25 |
| Working Capital | 48.02M |
Cash Flow
Lineage Cell Therapeutics, Inc. produced -22.11M in operating cash flow over the past twelve months. After subtracting -480,000.00 in capital expenditures, free cash flow totaled -22.59M - equivalent to -0.10 per share.
| Operating Cash Flow | -22.11M |
| Capital Expenditures | -480,000.00 |
| Free Cash Flow | -22.59M |
| FCF Per Share | -0.10 |
Margins
Lineage Cell Therapeutics, Inc. operates with a gross margin of 99.26, reflecting its pricing power and cost economics. The operating margin of -154.73 and net profit margin of -434.44 provide insight into operational efficiency.
| Gross Margin | 99.26 |
| Operating Margin | -154.73 |
| Pretax Margin | -468.86 |
| Profit Margin | -434.44 |
| EBITDA Margin | -149.83 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.08 |
| FCF Yield | -0.06 |
Scores
Lineage Cell Therapeutics, Inc. posts an Altman Z-Score of 368.60, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 368.60 |